For the Inventor, By the Inventor

Enter assignee name

Berkshire, United Kingdom

Sterix Limited

USPTO Granted Patents = 51

% Expired Patents = 70.6

EPO Patents = 12

Forward Citations = 149

Loading Chart...

Loading Chart...

51 inventors (with patents filed for the assignee):

Michael John Reed (45 out of 59 patents)

Barry Victor Lloyd Potter (41 out of 45 patents)

Atul Purohit (19 out of 23 patents)

4. Lok Wai Lawrence Woo (13 out of 15 patents)

5. Christian Bubert (7 out of 7 patents)

6. Matthew Paul Leese (6 out of 6 patents)

7. Olaf Peters (5 out of 16 patents)

8. Nigel Vicker (5 out of 8 patents)

9. Alexander Hillisch (5 out of 41 patents)

10. Eberhard Unger (5 out of 5 patents)

11. Christian Gege (4 out of 38 patents)

12. Gerhard Siemeister (4 out of 78 patents)

13. Oliver Brook Sutcliffe (4 out of 4 patents)

14. Barry Victor Potter (4 out of 10 patents)

15. Bertrand Leblond (3 out of 23 patents)

Core Competencies:

Aromatase Inhibitors

Steroid Sulphatase

Anti-Tumor Compounds

Endocrine-Dependent Tumors

Heterocyclic Compounds

Sulfamic Acid Esters

Polycyclic Sulphamate

Steroidal Compounds

Cell Cycling Inhibition

Estrogen Derivatives

Thioether Sulphamate Steroids

51 patents: Sort by Forward Citations

1. 8846737 - Compound (2014-09-30),

2. 8492570 - 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumor action (2013-07-23),

3. 8470860 - Phenyl-sulfamates as aromatase inhibitors (2013-06-25),

4. 8394825 - Compound (2013-03-12),

5. 8207152 - Methods for treating or preventing cancer by preventing, inhibiting, or arresting cell cycling (2012-06-26),

6. 8148415 - Sulfamic acid ester compounds useful in the inhibition of steroid sulphatase activity and aromatase activity (2012-04-03),

7. 8124614 - Steroidal compounds for inhibiting steroid sulphatase (2012-02-28),

8. 8119627 - Heterocyclic compounds as inhibitors of 17beta-HSD3 (2012-02-21),

9. 8030296 - Oestrogen-17-sulphamates as inhibitors of steroid sulphatase (2011-10-04),

10. 8026229 - Antitumor-active 2-alkoxyestradiol sulfamates (2011-09-27),

11. 8022224 - 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors (2011-09-20),

12. 8003783 - 17B-hydroxysteroid dehydrogenase inhibitors (2011-08-23),

13. 7968561 - Steroidal compounds as steroid sulphatase inhibitors (2011-06-28),

14. 7893284 - Oestrogen derivatives as inhibitors of steroid sulphatase (2011-02-22),

15. RE42132 - Antitumoral D-homoestra-1,3,5(10)-trien-3-yl 2-substituted sulfamates (2011-02-07),

Company Overview

Sterix Limited, based in Berkshire, GB, specializes in the development of innovative cancer treatment solutions. The company focuses on advanced therapeutic areas, particularly in the realm of endocrine-dependent tumors. Its core technologies include aromatase inhibitors and steroid sulphatase, alongside a range of anti-tumor compounds. Sterix is dedicated to addressing complex medical challenges through its expertise in heterocyclic compounds, sulfamic acid esters, and steroidal compounds, contributing to the evolving landscape of oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

51 Patents

#2 in Berkshire

#348 in United Kingdom

#13,788 in the World

Berkshire, United Kingdom

Sterix Limited

Forward Citations = 149

51 inventors:

Michael John Reed (45 out of 59 patents)

Barry Victor Lloyd Potter (41 out of 45 patents)

Atul Purohit (19 out of 23 patents)

4. Lok Wai Lawrence Woo (13 out of 15 patents)

5. Christian Bubert (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sterix Limited. Retrieved from https://idiyas.com/company/sterix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…